SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer and is the only automated insulin ...

Automated Insulin Dosing Software First to Receive New Classification by FDA All in-warranty t:slim X2 pump users in the United States will have the option to add the new feature free of charge via ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

A new software system that will let people with diabetes customize their treatment and automatically adjust their insulin levels was just approved for use by the Food and Drug Administration. It will ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...

The FDA approved its first automatic insulin dosing system designed to deliver correction boluses as well as adjust background insulin levels to help prevent bouts of high and low blood sugar in ...

Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...